CBP-1008 is under clinical development by Coherent Biopharma and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer). According to GlobalData, Phase I drugs for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CBP-1008’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CBP-1008 is under development for the treatment of solid tumors such as solid tumors including ER positive/Her2 positive breast cancer, esophageal cancer, gastric adenocarcinoma, colorectal cancer, breast cancer, bile duct cancer (cholangiocarcinoma), fallopian tube cancer, peritoneal cancer, lung squamous cell carcinoma, pancreatic cancer, epithelial ovarian cancer, triple-negative breast cancer (TNBC), head and neck cancer squamous cell carcinoma, colon cancer, cervical cancer and endometrial cancer. It was also under development for liver cancer. The drug candidate is a FR Alpha/TRPV6 bispecific ligand drug conjugated to monomethyl auristatin E (MMAE).
Coherent Biopharma overview
Coherent Biopharma is a clinical-stage biopharmaceutical company engaged in development and commercialization of bi-targeting XDC drugs which are targets tumor ligand-mediated drugs and tumor markers. The company is headquartered in Suzhou, Jiangsu, China.
For a complete picture of CBP-1008’s drug-specific PTSR and LoA scores, buy the report here.